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Protocol
AbstrACt
Introduction Cancer survival in England lags behind most 
European countries, due partly to lower rates of early stage 
diagnosis. We report the protocol for the evaluation of a 
multidisciplinary diagnostic centre-based pathway for the 
investigation of ‘low-risk but not no-risk’ cancer symptoms 
called the Suspected CANcer (SCAN) pathway. SCAN is a 
new standard of care being implemented in Oxfordshire; 
one of a number of pathways implemented during the 
second wave of the Accelerate, Coordinate, Evaluate (ACE) 
programme, an initiative which aims to improve England’s 
cancer survival rates through establishing effective routes 
to early diagnosis.
Methods and analysis To evaluate SCAN, we are 
collating a prospective database of patients referred onto 
the pathway by their general practitioner (GP). Patients 
aged over 40 years, with non-specific symptoms such as 
weight loss or fatigue, who do not meet urgent cancer 
referral criteria or for whom symptom causation remains 
unclear after investigation via other existing pathways, can 
be referred to SCAN. SCAN provides rapid CT scanning, 
laboratory testing and clinic review within 2 weeks. We 
will follow all patients in the primary and secondary 
care record for at least 2 years. The data will be used to 
understand the diagnostic yield of the SCAN pathway 
in the short term (28 days) and the long term (2 years). 
Routinely collected primary and secondary care data from 
patients not referred to SCAN but with similar symptoms 
will also be used to evaluate SCAN. We will map the routes 
to diagnosis for patients referred to SCAN to assess cost-
effectiveness. Acceptability will be evaluated using patient 
and GP surveys.
Ethics and dissemination The Oxford Joint Research 
Office Study Classification Group has judged this to be a 
service evaluation and so outside of research governance. 
The results of this project will be disseminated by peer-
reviewed publication and presentation at conferences.
bACkground 
England’s rates of cancer survival lag behind 
many other European countries, and late 
stage at diagnosis is thought to play a large 
part in this.1 2 Twenty-one per cent of cancers 
are diagnosed as an emergency, which is 
associated with advanced tumour stage and 
increased mortality in the first year post-diag-
nosis.3 4 It is estimated that, if diagnosed early, 
5000 cancer deaths could be prevented every 
year for breast, colorectal and lung cancers 
alone.2 5 The Accelerate, Coordinate, Eval-
uate (ACE) programme is an early diagnosis 
initiative supported by the National Health 
Service (NHS) England, Cancer Research UK 
(CRUK) and Macmillan Cancer Support.6 It 
was formed to help improve England’s cancer 
survival rates by generating evidence on how 
best to configure diagnostic pathways to drive 
a shift from late to early cancer at diagnosis, 
strengths and limitations of this study
 ► The  Suspected CANcer (SCAN) pathway will be 
evaluated in relation to diagnostic yield, time to 
diagnosis, cost-effectiveness, patient satisfaction 
and incidental diagnoses.
 ► Data from both the primary and secondary 
care record will be used to populate a bespoke 
prospective database detailing the cohort of patients 
evaluated by the SCAN pathway.
 ► A general  practitioner or patient-level 
randomised  implementation of SCAN was not 
feasible within the constraints of the local health 
system, nor a randomised stepped-wedge roll-
out to the six Oxfordshire Clinical Commissioning 
Group (CCG) regions.
 ► Instead, a pragmatic service evaluation is being 
conducted around a phased roll-out of the pathway 
against the previous standard of care in the same 
region, operated by the same CCG.
 ► The findings of this evaluation will only indicate 
SCAN’s effectiveness in Oxfordshire and should not 
be generalised to the rest of England.
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reduce the number of cancers diagnosed as an emer-
gency and improve patient experience.
The first wave of ACE comprised around 60 projects 
aiming to evaluate local initiatives to develop a national 
body of evidence to inform cancer commissioning.7 A 
weakness in the current system identified during Wave 1 
was the lack of a clear urgent referral pathway for patients 
with non-specific but concerning symptoms known to be 
associated with a range of cancer sites, such as fatigue, 
abdominal pain and weight loss.8 Consequently, before 
reaching a cancer diagnosis, these patients often have 
multiple tests and non-urgent referrals resulting in 
delays in diagnosis.9 The Independent Cancer Taskforce 
outlined the need to explore new models of care to speed 
up diagnosis in patients with non-specific symptoms, 
making references to the multidisciplinary diagnostic 
centre (MDC) concept.10 ACE Wave 2 was set up to facil-
itate the development and evaluation of a small number 
of MDC-based pathways in the English NHS.6 These 
pathways are implemented as standards of care in partic-
ipating regions, in addition to site-specific urgent cancer 
referral pathways.
Oxfordshire’s Suspected CANcer (SCAN) pathway 
emulates a Danish MDC pathway, the non-spe-
cific symptoms and signs of cancer patient pathway 
(NSSC-CPP).11 Patients first undergo a panel of diag-
nostic investigations including blood and urine tests and 
diagnostic imaging. If no diagnosis is made, but cancer 
or another serious disease is suspected, the patient is 
referred to the MDC.11 12 The MDC is a diagnostic unit 
with access to a broad range of investigations and specialist 
expertise in managing patients with non-specific symp-
toms. Of 1278 patients referred to the NSSC-CPP pathway 
by their general practitioners (GPs), a cross-sectional 
study reported that 16% of patients were diagnosed with 
cancer.13 The most common symptoms recorded were 
weight loss (53%), fatigue (50%) and pain (37%). The 
most common clinical findings were ‘affected general 
condition’ (36%), GP ‘gut feeling’ (23%) and abnormal 
abdominal examination (13%). Forty-eight per cent 
of patients were referred with abnormal blood test 
results. Cancer was diagnosed across a broad range of 18 
subgroups, the most common of which were lung (18%), 
colorectal (13%), haematological (10%), pancreatic 
(9%) and upper gastrointestinal (8%).13 A later cohort 
study including 938 patients referred to the NSSC-CPP 
reported that 35% were diagnosed with serious disease 
within 3 months, of which one-third had cancer.14
As is the case in the UK, healthcare in Denmark is 
mostly free to access for residents, and Danish GPs act 
as ‘gatekeepers’ to specialist services.15 Five-year survival 
rates for several cancer types are also among the lowest 
in Organisation for Economic Cooperation and Devel-
opment countries.15 Both countries have introduced a 
1-month standard for the time between referral and diag-
nosis to increase the proportion of cancers diagnosed at 
an early stage.15 16 Furthermore, following the introduc-
tion of cancer pathways in Denmark which incorporate 
patient review by multidisciplinary teams (MDTs), waiting 
times have significantly reduced across almost all cancer 
types.17 The similarities between the Danish and UK 
health systems, the challenges faced by both and the 
improvements brought about by MDC-based pathways 
suggest that these pathways for non-specific symptoms 
warrant evaluation in the UK. At the time of writing, 
we retrieved no peer-reviewed articles detailing MDC 
pathways for cancer diagnosis in the UK, and only one 
conference abstract describing 91 patients assessed via an 
alternative MDC pathway developed during ACE Wave 1 
in London.18 Robust evaluation of the SCAN pathway has 
the potential to contribute to the evidence base for the 
MDC concept in cancer diagnosis. We report here the 
protocol for the SCAN pathway evaluation.
AIM
The aim of this study is to evaluate the SCAN pathway, a 
new standard of care for the rapid investigation of patients 
with non-specific cancer symptoms in Oxfordshire. SCAN 
will be evaluated in terms of how well it meets its objec-
tives, which are detailed below.
objectives
In line with the CRUK ACE initiative which aims to reduce 
late and increase early cancer diagnosis, decrease cancer 
diagnoses made through emergency presentations and 
improve patient experience,6 the objectives of the SCAN 
pathway are to:
 ► reduce time from initial primary care presentation 
with symptoms to diagnosis
 ► achieve a higher proportion of early stage cancer at 
diagnosis
 ► improve patient experience of the diagnostic pathway
 ► establish whether the MDC model is cost-effective.
setting
Oxfordshire’s cancer incidence (600 cases per 100 000) 
is lower than the UK average (615 cases per 100 000). 
Cancer mortality (261 per 100 000) is also lower than the 
national average, with fewer cancers diagnosed through 
emergency presentation (17.1% vs 20.1%) and more 
patients diagnosed at an early stage (56.8% vs 54.3%) 
than the national average.19 Comprising a predominantly 
white (90.85%) population, Oxfordshire has smaller 
foci of Asian (4.84%), Black (1.75%) and mixed ethnic 
(2.02%) groups. Black and minority ethnic communi-
ties form 22.4% of Oxford city’s population, with lower 
proportions in more rural districts: 7.8% in Cherwell and 
3.2% in West Oxfordshire (source: 2011 Census20). Rural 
districts (67%) rank in the 10% least deprived, and urban 
(33%) in the 20% most deprived in England. There are 
no ACE Wave 1 sites in Oxfordshire.
The Oxfordshire Clinical Commissioning Group (CCG) 
serves a population of over 700 000 through 70 general 
practices.21 Oxford University Hospitals NHS Foundation 
Trust (OUHFT) is made up of four hospitals providing 
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a range of specialist services (John Radcliffe Hospital, 
Churchill Hospital, Nuffield Orthopaedic Centre and the 
Horton General Hospital). SCAN imaging takes place at 
the Churchill Hospital, and the SCAN MDC is located at 
the John Radcliffe Hospital. SCAN links with the Oxford 
Allied Health Science Network (AHSN) imaging network, 
aiming to develop a model for expansion through the 
seven adjoining NHS network trusts.
the sCAn pathway
SCAN retains the GP’s gate-keeping role, requiring 
patients to first attend their GP with symptoms to access 
the pathway through GP referral.22 The SCAN referral 
algorithm was developed by consensus between an MDT 
including GPs, radiologists, physicians and health service 
researchers (online supplementary appendix 1). It incor-
porates age-thresholds and ‘low-risk but not no-risk’ 
symptoms that fall outside of existing urgent 2-week-wait 
(2ww) referral pathways based on the National Institute 
for Health and Care Excellence NG12 suspected cancer 
guidelines,23 but remain predictive of cancer in primary 
care.
SCAN will be opened up sequentially to GPs in each 
of the six subregions of Oxfordshire CCG, to ensure that 
the service has enough capacity to meet demand. The 
first region opened on 15 March 2017 and the second on 
5 June 2017. In response to demand, regions three and 
four were opened on 6 September 2017, and the final two 
regions are expected to open by 9 November 2017.
Estimated referral rate
We used the following data to estimate expected referral 
rates: (1) Oxfordshire population statistics20; (2) the 
number of GPs in Oxfordshire21; (3) the referral rate 
reported for the Danish NSSC-CPP pathway12; (4) the 
estimated prevalence of non-specific symptoms meeting 
SCAN referral criteria in primary care populations, 
derived from the control groups of primary care-based 
case–control studies.24 Using these sources, an estimate 
of 20–40 referrals per week was anticipated, taking into 
account that not all patients presenting to primary care 
with qualifying symptoms will be referred by their GP: 
symptoms may not occur in isolation or a pre-existing 
condition will provide explanation; GPs may identify an 
alternative explanation for new symptoms negating the 
need for referral; patients may be referred by other routes 
or patients may decline referral.
referral criteria
A structured standardised electronic referral form has 
been disseminated to all GPs in Oxfordshire (online 
supplementary appendix 2). If there is no other urgent 
referral pathway for the clinical scenario, patients 
aged ≥40 years are accepted if their GP is concerned about 
cancer or serious disease following face-to-face primary 
care assessment of individual or combined ‘low-risk but 
not no-risk’ symptoms. In addition, patients may be 
referred based on their GP’s clinical suspicion of cancer 
or serious disease (their ‘gut feeling’).25 26 GPs are also 
requested to indicate their suspicion of malignancy at this 
stage. The essential referral criteria are:
1. There is no other urgent referral pathway suitable for 
this clinical scenario.
2. Patient is ≥40 years of age
3. Patient has at least one of the following:
 ► Unexplained weight loss
 ► Severe unexplained fatigue
 ► Persistent nausea or appetite loss
 ► New atypical pain
 ► Unexplained laboratory test finding
 ► GP clinical suspicion of cancer or serious disease/ GP 
'gut feeling'
stages of the pathway
As part of their initial work-up to exclude more common 
causes of non-specific symptoms in primary care, GPs 
will conduct investigations essential to allow access 
to the SCAN pathway: creatinine (necessary prior to 
intravenous contrast) and thyroid function tests (hypo-
thyroidism as a cause of fatigue). The referral form 
completed by the GP constitutes a referral for all aspects 
of the SCAN pathway, including the CT scan and blood 
tests. Once referred, a member of the SCAN team (the 
SCAN pathway navigator) assumes clinical responsibility 
for the patient, confirms that the patient meets the inclu-
sion criteria, orders and coordinates the CT and blood 
tests, and provides a point of contact for the patient. 
Demographic and clinical information is captured by the 
GP referral form.
Consent: At the point of referral, patients are given a 
participant information sheet detailing the SCAN pathway 
and consent form (online supplementary material 3) to 
allow their anonymised medical records to be used for 
the purposes of evaluating the pathway. Patients are given 
time to take the information away and consider whether 
they wish to participate. If patients decide to participate, 
they are asked to take the consent form to the initial 
appointment, at which time they may ask any outstanding 
questions. Patients who do not wish to have their medical 
records used may still be referred onto the SCAN pathway 
but will not be followed up for the purposes of the evalua-
tion. At the time of writing, none of the patients accepted 
onto SCAN had refused consent.
Stage 1: GP direct access triage tests: At the first hospital 
appointment, a panel of standard diagnostic investi-
gations with rapid turnaround (request-test-report) 
of <7 days are performed. These tests include a panel of 
blood tests, faecal immunochemical testing and appro-
priate low-dose CT imaging with separate reporting lines 
to ensure report turnaround times of 24 hours (box). 
Separate reporting lines for radiology facilitate evalua-
tion, and the AHSN imaging consultants provide addi-
tional reporting capacity to ensure turnaround times.
Stage 2: The clinical information obtained in stage 1 
directs the patient’s subsequent progression through the 
pathway. Patients are either referred:
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a. to a cancer MDT or specialist clinic via an existing 
urgent pathway
b. for additional direct access investigation within 
1 week prior to clinician review
c. to the MDC for medical review.
The referring GP receives a copy of the CT report and 
a letter from the SCAN team explaining which pathway 
their patient has been referred to. Any urgent findings 
are communicated to the GP via telephone. Any tele-
phone conversations are followed by a letter detailing the 
conversation and the actions the GP and SCAN team have 
agreed to.
Stage 3: If symptom causation remains unclear after 2a 
or 2b, the patient is automatically referred to the MDC 
(2c). At the point of referral to the MDC, the accepting 
hospital clinician becomes the responsible MDC clini-
cian. At the MDC, the sequence of testing to further 
explain the patient’s clinical problem is determined by 
the accepting clinician.
Stage 4: All patients who consent to participate in the 
SCAN pathway will be followed up for 2 years, including 
patients for whom cancer and serious disease is excluded. 
The GP will receive a structured follow-up plan allowing 
return to the MDC to avoid repeat CT scanning for 
patients with new, recurrent or persistent symptoms 
meeting SCAN entry criteria. The patient journey along 
the SCAN pathway is summarised in online supplemen-
tary appendix 4.
MEthods for EvAluAtIon
The sequential implementation of the SCAN pathway in 
Oxfordshire has allowed a short informal ‘pilot’ period 
during which we have been able to assess the functioning 
of the pathway to address any issues that may arise before 
it is opened to all GPs. A detailed analysis of the consec-
utive cohort of patients referred to the SCAN pathway, 
whose medical records are gathered retrospectively and 
followed up prospectively, will form the basis of the path-
way’s evaluation. We will also evaluate the pathway in 
terms of its cost-effectiveness as well as a number of other 
indicators detailed below, thereby following the frame-
work for evaluating complex interventions as laid out by 
the Medical Research Council.27
sCAn database
The OpenClinica computer package (https://www. 
openclinica. com/) is being used to store a database of 
demographic information, symptoms leading to referral, 
investigations performed, referrals made, appointments, 
diagnoses and short-term and long-term outcomes for all 
patients referred to SCAN. The time-point and outcome 
of each clinical encounter will be recorded for at least 
2 years following referral to identify short-term and long-
term diagnoses.
Patients will enter the database on the date the SCAN 
team confirms their eligibility. At this point, data collected 
retrospectively from the primary care record using the 
autopopulating referral form (online supplementary 
appendix 2) will be manually entered into the SCAN data-
base, and prospective data collection will begin using the 
OUHFT record.
The SCAN pathway will be evaluated based on its short-
term and long-term diagnostic yield and its cost-effec-
tiveness in terms of the resources and time needed for a 
diagnosis to be reached. Patients’ route to diagnosis and 
satisfaction with their experience of the SCAN pathway 
will also be evaluated as secondary outcomes. The primary 
and secondary points of evaluation are described in detail 
below.
Primary points of evaluation
Diagnostic yield
a. Short-term: diagnoses made within 28 days of 
referral.
b. Cancer site and stage at diagnosis: histopathology or 
MDT determined.
c. Non-cancer diagnoses determined by MDC or an-
other specialist clinic.
d. Long-term: diagnoses made within 2 years of refer-
ral confirmed by primary and secondary care data-
base review at 2 years.
secondary points of evaluation
a. To map the route to diagnosis for SCAN patients 
in terms of time intervals associated with diagnosis 
(ie, each diagnostic interval in line with the Aarhus 
statement28) and the number and sequence of 
patient encounters (investigations and appoint-
ments leading to diagnosis), including the num-
ber of diagnoses made following an emergency 
presentation.
b. To quantify incidental findings detected by the 
SCAN pathway.
c. To evaluate the cost-effectiveness of the SCAN 
pathway.
d. To assess patient and GP satisfaction with the SCAN 
pathway.
box tests performed at sCAn stage 1
 ► Full blood count
 ► Erythrocyte sedimentation rate
 ► C reactive protein
 ► Urea and electrolytes
 ► Creatinine
 ► Calcium
 ► Phosphate
 ► HbA1c
 ► Thyroid function
 ► CA125 (females)
 ► PSA (males)
 ► Faecal immunochemical testing
 ► CT (thorax, abdomen and pelvis)
CA125, cancer antigen 125; HbA1c, glycated haemoglobin; PSA, 
prostate-specific antigen; SCAN, Suspected CANcer.
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sCAn implementation
The implementation of the SCAN pathway will be carried 
out in six stages corresponding to the six Oxfordshire 
CCG subregions. This pragmatic decision was made to 
allow the OUHFT and CCG to monitor GP uptake of 
the pathway in real-time to ensure that the capacity of 
the pathway is not exceeded and to allow early prob-
lems with service delivery to be overcome. This is an 
opportunity for a rigorous evaluation of the pathway in 
real-time, in the same county and which will avoid the 
potential confounding that could arise from comparing 
SCAN patients to patients in different regions operated 
by different CCGs.
Pre-SCAN period: Before having access to SCAN, GPs in 
each region will be asked to prospectively identify patients 
meeting SCAN entry criteria and to complete a ‘dummy’ 
comparator cohort data collection form to be submitted 
by email to a secure CCG email inbox (online supple-
mentary appendix 5). Anonymised referral information 
is extracted electronically to maintain patient confiden-
tiality. This group of comparator patients will provide 
data about patients receiving the standard of care prior 
to the introduction of SCAN (the new standard of care) 
who are diagnosed via alternative routes, such as 2ww 
pathways, non-urgent specialist referral or by emergency 
presentation. In addition, an audit of local GP electronic 
records of patients with symptoms meeting SCAN referral 
criteria, but referred via other routes for investigation, 
will provide further contemporaneous data against which 
to evaluate SCAN.
SCAN period: Depending on uptake of the pathway, each 
CCG region will transition to the SCAN pathway over 
time. The set-up and evaluation of the SCAN pathway is 
currently funded for a period of at least 2 years of patient 
intake and 2 years of follow-up. ACE Wave 2 projects are 
expected to report results in late 2018.6 Following this, 
it is anticipated that Oxfordshire CCG will adopt SCAN 
indefinitely and will take on its funding as the MDC 
model is of interest to NHS England.
Follow-up: All patients will be followed up in the primary 
and secondary care record for at least 2 years from entry 
by the pathway navigators.
stAtIstICAl AnAlysIs
Primary point of evaluation: diagnostic yield
Our primary point of evaluation is yield from the new 
SCAN pathway with respect to the number and propor-
tion of patients (1) with a new diagnosis or with disease 
excluded within 28 days and (2) with a diagnosis made 
within 2 years of referral. For newly diagnosed patients, 
we will report the diagnostic interval (first presentation 
to primary care to date of diagnosis), the doctor interval 
(first presentation to primary care to the first primary 
care investigation), the primary care interval (first presen-
tation to primary care to referral to secondary care), 
secondary care interval (referral to secondary care to 
start of treatment) and the treatment interval (diagnosis 
to the start of treatment).28 For patients with indetermi-
nate findings which require further investigation, we will 
report the number of follow-up consultations or investiga-
tions up until discharge.
The analysis of long-term outcomes will be conducted 
after 2 years, where missed diagnoses (false negatives) will 
be defined as diagnoses not picked up in the short term 
but in the longer term and attributed to the initial symp-
tomatic presentation allowing entry to the cohort. Within 
this analysis, the proportion of patients diagnosed with 
cancer and surviving 1 year will be ascertained.
secondary points of evaluation: route to diagnosis, cost-
effectiveness, gP and patient satisfaction
For the secondary outcome assessing routes to diagnosis, 
the number (and type) of healthcare contacts required 
to make a diagnosis will be counted for each participant 
starting from the initial primary care visit for the symp-
toms permitting referral to SCAN. The number of patients 
diagnosed following an emergency presentation will also 
be counted. Medians and IQRs will be calculated for each 
of the diagnostic intervals (days) stratified by symptom 
group, disease type, disease site and severity/stage where 
possible and presented graphically using box plots.
Incidental findings: Incidental findings are radiological 
abnormalities not caused by the symptoms being investi-
gated that may drive further imaging and concern.29 To 
understand incidental findings in patients referred to 
SCAN, demographic, clinical and radiological informa-
tion will be extracted from the SCAN database. Imaging 
findings will be categorised per anatomical location. Each 
finding will be defined as of potential clinical importance 
(eg, cancer, aneurysms and cardiac findings), and prob-
able or consistent with, or equivocal or unlikely to explain 
the symptoms at the time of referral. In the case of multiple 
lesions of the same type, the number will be recorded and 
reported. As the SCAN pathway uses ungated low-dose 
CT imaging, an approach to avoid the over interpreta-
tion of cardiac findings was developed. The TeraRecon 
software package (https://www. terarecon. com/) will be 
used to look at any coronary artery calcification, and an 
Agatson score will be calculated. This approach has been 
adopted due to the success that has been reported in a 
number of American studies assessing the prognostic 
accuracy of calcium scoring coronary arteries from an 
ungated low-dose CT scan.30–34 The data gathered from 
patients’ medical records will be used to evaluate the 
ability of this protocol to show relevant coronary artery 
calcification. Incidental findings that have potential clin-
ical importance will be followed up according to the stan-
dards issued by the American College of Radiologists, the 
British Thoracic Society and the Royal College of Radiolo-
gists.35–37 In addition, any further investigations (eg, MRI) 
required to determine if CT findings are truly incidental 
will be recorded as part of mapping routes to diagnosis.
Patient survey: All patients who consent to participate 
in the evaluation of the SCAN pathway will be asked to 
complete a set of questionnaires about their experience 
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of the pathway. The Consequence of Screening (COS) 
questionnaire (originally Psychological Consequences 
Questionnaire)38 will be given to patients shortly after 
referral to the MDC and then again 6–12 months after 
their referral. Individual items on the COS scales will 
be combined into themes of anxiety, behaviour, sense of 
dejection and sleep, and item scores added together. COS 
domain scores will be compared across patients who had 
a confirmed diagnosis of cancer or other serious disease, 
false positive finding and probably benign finding using 
non-parametric tests.
Patient satisfaction surveys will also be distributed to all 
patients (regardless of participation in the pathway eval-
uation) at the end of their CT scan. This questionnaire 
has been designed to evaluate the patient’s experience 
of the staff and the service provided by the radiology 
department.
GP satisfaction survey: A brief satisfaction survey will 
be distributed to all participating GPs. This survey will 
assess satisfaction with the ease of use of the SCAN 
pathway, speed with which referred patients are seen 
by the SCAN team and the quality of the information 
provided to GPs by the SCAN team both in terms of the 
functioning and purpose of the pathway and the results 
of the diagnostic tests undergone by their patient(s). 
The survey will be distributed and completed online 
using the Bristol Online Surveys tool (https://www. 
onlinesurveys. ac. uk/).
Cost-effectiveness: The cost-effectiveness of the SCAN 
pathway will be assessed from the perspective of the NHS 
in England, using a within-trial analysis. Each patient 
encounter from referral to SCAN up until a final diag-
nosis is made or excluded will be recorded. The outcome 
will be incremental cost-effectiveness compared with 
the pre-SCAN pathway, with effectiveness measured in 
unit reduction in time to diagnosis, and in additional 
diagnosis within 28 days. The comparison group will be 
the pre-SCAN patient cohort. Although the numbers of 
comparator patients should closely resemble those of 
patients referred to the pathway as the inclusion criteria 
are identical, we expect comparator patient numbers to 
be lower as GPs are requested to take time to complete 
the referral forms with no tangible benefit to their 
patients. Due to the expected lower response rate, we will 
supplement comparator data from GPs with an audit of 
Oxfordshire surgeries with the appropriate data sharing 
agreement, approximately 60 practices, up to March 
2017. The resource use of patients in the SCAN pathway 
and its comparator will be estimated from the data-
base and costed using national unit costing databases.39 
In addition, patients will be asked to complete the UK 
Cancer Costs Questionnaire40 to record ongoing financial 
and opportunity costs. Sensitivity analyses will be carried 
out on the key assumptions of the evaluation, including 
resource use assumptions, the impact of adjusting for 
baseline characteristics and extending the analysis to 
cost utility.
Eligible patients not referred to sCAn
The phased introduction of the SCAN pathway affords 
comparison with outcomes under the previous standard 
of care for patients meeting SCAN referral criteria. This 
will include patients with SCAN eligible symptoms iden-
tified by their GPs and diagnosed via alternative routes, 
for example, by 2ww pathways, non-urgent specialist 
referral or by emergency presentation. Robust statistical 
comparisons between SCAN and the period prior to 
SCAN may be limited dependent on gathering data on 
a sufficient number of patients with symptoms meeting 
SCAN referral criteria who are not referred to SCAN, 
which is in turn dependent on GPs completing the 
comparator referral forms. Therefore, the data collected 
on patients not referred to SCAN provided by GPs will be 
supplemented with an audit of the primary care record 
and will be presented in tables with descriptive statistics, 
only comparing SCAN and pre-SCAN outcomes when 
appropriate.
sample size
In order to have power >80% (alpha=5%) and if the 
SCAN pathway halves the average length of the diagnostic 
interval compared with usual care (HR=2), we would 
need at least 43 patients diagnosed with cancer during 
the pre-SCAN period and at least 173 patients diagnosed 
with cancer following the introduction of the pathway.41 If 
15% of patients presenting to their GP with non-specific 
symptoms have cancer,12 we need to recruit at least 1460 
patients.
data handling and data management
A data management plan (DMP) is in place outlining in 
detail the specific procedures to ensure that high-quality 
data are produced for statistical analysis. The DMP was 
reviewed and signed off by all relevant parties prior to 
data management activities commencing.
Data will be collected electronically in OpenClinica 
(https://www. openclinica. com/), and data validation 
is achieved through electronic programmed checks or 
through manual review of listing outputs. All discrepan-
cies generated by electronic validation checks or manual 
listings will be reviewed by the data manager.
EthICs And dIssEMInAtIon
Evaluation of a newly established service/adopted 
pathway does not require research governance as such 
activity falls outside of the definition of research as set 
out by the Health Research Authority (HRA) and would 
not be considered research in the NHS. As such, this 
evaluation is not subject to the Department of Health’s 
Research Governance Framework for Health and Social 
Care (2005). This opinion can be reviewed by reference 
to the HRA’s algorithm, available at http://www. hra- 
decisiontools. org. uk/ research/ and attendant leaflet, 
Defining Research or by reference to the Healthcare 
Quality Improvement Partnership’s Guide for Clinical 
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Audit, Research and Service Review.42 In addition, a 
Privacy Impact Assessment concluded that individual 
patient consent was not necessary to collect data on the 
comparator patients. The primary reason for this was that 
obtaining consent was likely to cause unnecessary distress 
to patients who were not yet able to make use of the new 
pathway. Instead, a data sharing agreement was signed by 
all participating GP surgeries, and all comparator data 
will be sent electronically to the CCG Commissioning 
Support Unit and pseudonymised before being shared 
with the SCAN team.
The results of this evaluation will be reported in 
peer-reviewed journals and on the websites of the various 
ACE Wave 2 funding bodies. Abstracts for oral or poster 
presentations will be submitted to national and interna-
tional conferences. Data resulting from this study will be 
made available following a request to the authors.
strengths and limitations
This is the first published protocol for the evaluation 
of an MDC pathway based in the UK. The evaluation 
outlined above will provide detailed information on the 
diagnostic yield and time to diagnosis for comparison 
of the MDC model with existing routes to diagnosis in 
the NHS. Our focus on incidental findings and cost-ef-
fectiveness will add valuable evidence about the value of 
early CT scanning of patients with non-specific symptoms, 
especially in response to concerns about overdiagnosis.
Our evaluation, however, has some limitations. First, 
due to the pragmatic nature of SCAN’s implementation, 
the evaluation has had to take into account resource 
constraints and logistical realities of Oxfordshire’s health 
system. Consequently, we have been unable to randomise 
individual patients or GPs to the SCAN pathway, nor could 
we randomise the sequence of a stepped-wedge roll-out of 
SCAN across CCG regions. Second, collection of compar-
ator data is reliant on local GPs opting to do so as an 
additional task in an already busy health service without 
additional financial incentive. We are supplementing 
this approach with a retrospective review of primary 
care records to identify eligible patients pre-SCAN. The 
method of symptom capture using this approach is in 
development but may be limited to retrospective electron-
ic-coded entries. Due to these factors, the generalisability 
of our findings outside of Oxfordshire will be limited.
ConClusIon
Cancer prognosis improves with early diagnosis, but the 
UK lags behind many European countries in terms of the 
proportion of patients diagnosed at an early stage. For 
this reason, the Independent Cancer Taskforce has high-
lighted the need for alternative routes to diagnosis to be 
explored and has made specific reference to MDC-based 
pathways. The SCAN pathway is such an MDC-based 
pathway which has been adopted in Oxfordshire with 
the aim of reducing the time from initial presentation of 
non-specific but concerning symptoms to diagnosis and 
increasing the proportion of cancers diagnosed at an early 
stage. We will evaluate the ability of the SCAN pathway to 
meet these aims over 2 years, will assess the patient expe-
rience of the diagnostic pathway and appraise the cost-ef-
fectiveness of the pathway.
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